EUVIMEDEUVIMED entdecken
Kohortenstudie

How long should survivors of pediatric medulloblastoma and ependymoma be screened for recurrence? A retrospective cohort study

Thomas F C Meulendijks iD, Gertjan J L Kaspers iD, Vijay Ramaswamy iD, Derek S Tsang iD, Suzanne Laughlin iD, Julie Bennett iD, Paul C Nathan iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.70016 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Thomas F C Meulendijks und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Ependymoma, Medulloblastoma, Neoplasm Recurrence, Local, Cancer Survivors. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrence is the most common cause of late mortality in pediatric brain tumor survivors. However, it is unclear how long such patients should be monitored with periodic neuroimaging. Therefore, we investigated the utility of neuroimaging surveillance for recurrence ≥5 years post diagnosis in survivors of pediatric medulloblastoma and ependymoma. We conducted a retrospective study of survivors of medulloblastoma or ependymoma treated between 2000 and 2017. Eligible survivors were disease‐free 5 years after diagnosis and underwent magnetic resonance imaging surveillance ≥5 years after diagnosis. Medulloblastoma survivors with a history of recurrence

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpendymomaMedulloblastomaNeoplasm Recurrence, LocalCancer SurvivorsCerebellar NeoplasmsBrain NeoplasmsHumansMaleFemaleChildRetrospective StudiesChild, PreschoolInfantMagnetic Resonance ImagingAdolescentNeuroimaging

Stichwörter der Autor:innen

ependymomamedulloblastomaneuroimagingrecurrencesurveillance

Autor:innen und Institutionen

  • Division of Hematology and Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Radiation Medicine Program, University Health Network, Toronto, Ontario, Canada.
  • Faculty of Medicine, University of Amsterdam, Amsterdam, The Netherlands.
  • Departments of Pediatric Oncology/Hematology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Thomas F C Meulendijks, Gertjan J L Kaspers, Vijay Ramaswamy, Derek S Tsang, Suzanne Laughlin, Julie Bennett, Paul C Nathan

Zitieren

APA

Meulendijks, T. F. C., Kaspers, G. J. L., Ramaswamy, V., Tsang, D. S., Laughlin, S., Bennett, J., & Nathan, P. C. (2025). How long should survivors of pediatric medulloblastoma and ependymoma be screened for recurrence? A retrospective cohort study. International Journal of Cancer. https://doi.org/10.1002/ijc.70016

Vancouver

Meulendijks TFC, Kaspers GJL, Ramaswamy V, Tsang DS, Laughlin S, Bennett J, et al. How long should survivors of pediatric medulloblastoma and ependymoma be screened for recurrence? A retrospective cohort study. International Journal of Cancer. 2025. doi:10.1002/ijc.70016

BibTeX
@article{Meulendijks2025,
  author = {Meulendijks, Thomas F C and Kaspers, Gertjan J L and Ramaswamy, Vijay and Tsang, Derek S and Laughlin, Suzanne and Bennett, Julie and Nathan, Paul C},
  title = {How long should survivors of pediatric medulloblastoma and ependymoma be screened for recurrence? A retrospective cohort study},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.70016}
}
Kostenlos starten →